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Abstract
Idiopathic pulmonary fibrosis (IPF) is a progressive, usually fatal, form of interstitial
lung disease characterized by failure of alveolar re-epithelialization, persistence of fibrob-
lasts/myofibroblasts, deposition of extracellular matrix, and distortion of lung architecture
which ultimately results in respiratory failure. Clinical IPF is associated with a histopatho-
logical pattern of usual interstitial pneumonia (UIP) on surgical lung biopsy. Therapy for
this disease with glucocorticoids and other immunomodulatory agents is largely ineffective
and recent trials of newer anti-fibrotic agents have been disappointing. While the inciting
event(s) leading to the initiation of scar formation in UIP remain unknown, recent advances
in our understanding of the mechanisms underlying both normal and aberrant wound heal-
ing have shed some light on pathogenetic mechanisms that may play significant roles in this
disease. Unlike other fibrotic diseases of the lung, such as those associated with collagen vas-
cular disease, occupational exposure, or chemotherapeutic agents, UIP is not associated with
a significant inflammatory response; rather, dysregulated epithelial–mesenchymal interac-
tions predominate. Identification of pathways crucial to fibrogenesis might offer potentially
novel therapeutic targets to slow or halt the progression of IPF. This review focuses on
evolving concepts of cellular and molecular mechanisms in the pathogenesis of UIP/IPF.
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Introduction
Pulmonary fibrosis is the end result of a variety of
insults to the lung. Antecedent injuries to the lung may
be recognized, as with chemotherapy [1], collagen vas-
cular disease [2], or inhalational injury [3]. However,
in idiopathic pulmonary fibrosis (IPF) [also termed
cryptogenic fibrosing alveolitis (CFA)], the inciting
insult remains unidentified. In 1969, Liebow and Car-
rington first classified interstitial pneumonias into five
distinct categories, based on histological features [4]
(Table 1). Subsequently, giant cell interstitial pneu-
monia (GIP) was excluded from the category of IPF
because GIP is the histological manifestation of hard-
metal pneumoconiosis [5]. The classification scheme
of interstitial lung diseases has undergone numerous
revisions and currently, seven distinct subtypes of idio-
pathic interstitial pneumonia (IIP) have been proposed
by the American Thoracic Society/European Respi-
ratory Society (ATS/ERS): usual interstitial pneu-
monia (UIP), desquamative interstitial pneumonia
(DIP), respiratory bronchiolitis interstitial lung dis-
ease (RB–ILD), acute interstitial pneumonia (AIP),
non-specific interstitial pneumonia (NSIP), crypto-
genic organizing pneumonia (COP), and lymphoid
interstitial pneumonia (LIP) (Table 2) [6]. Of these
histopathological subtypes, UIP is the histological pat-
tern that characterizes patients with the clinical entity
of IPF [6]. Based on the high proportion of UIP/IPF
among the IIPs, its overall poor prognosis, and its
unresponsiveness to currently available therapy, the
remainder of this review will focus on mechanisms
of fibrosis associated with UIP/IPF.
Epidemiology and clinical features of IPF
Epidemiology
IPF is a relatively rare disease, although the true
prevalence is unknown. Prevalence rates of three
to six cases per 100 000 population are often cited
[7], but a recent study in Finland demonstrated a
nationwide prevalence of 16–18 per 100 000 [8].
Subgroup analyses demonstrate a higher prevalence
of IPF among older individuals. In one study, the
prevalence of IPF was 2.7 per 100 000 population
among adults between age 35 and 44 years but rose
to 175 per 100 000 population in individuals older
than 75 years [9]. The mean age at diagnosis of
IPF is 66 years [7,10]. IPF is more common in
males than in females and some studies indicate that
an environmental or occupational exposure to dusts,
organic solvents, or urban pollution increases the risk
of developing IPF [7,11,12].
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Table 1. Original classification of interstitial pneumonia
(Liebow)∗
Bronchiolitis obliterans with interstitial pneumonia (BIP)
Desquamative interstitial pneumonia (DIP)
Giant cell interstitial pneumonia (GIP)
Lymphoid interstitial pneumonia (LIP)
Usual interstitial pneumonia (UIP)
∗ Adapted from ref 4.
Table 2. New classification of idiopathic interstitial pneumonias
(ATS/ERS)∗
Acute interstitial pneumonia (AIP)
Cryptogenic organizing pneumonia (COP)
Desquamative interstitial pneumonia (DIP)
Respiratory bronchiolitis–interstitial lung disease (RB-ILD)
Lymphoid interstitial pneumonia (LIP)
Non-specific interstitial pneumonia (NSIP)
Usual interstitial pneumonia (UIP)
∗ Adapted from ref 6.
Recently, data have emerged linking both genetic
and environmental factors to the development of
UIP/IPF. A familial form of UIP has been reported
in 0.5–2.2% of cases [13] and a number of candidate
genes encoding both cytokines and structural proteins
have been identified in large kindreds [14,15]. Using
linkage analysis, Thomas et al demonstrated a muta-
tion in the pro-surfactant protein-C (proSP-C) gene
encoding a leucine → glutamine substitution in the
C-terminus [14]. This mutation results in improper
intracellular trafficking of proSP-C in type II alveolar
epithelial cells, as evidenced by electron microscopy
showing aberrant subcellular localization of the protein
and abnormal lamellar bodies [14]. These findings sug-
gest that in this kindred, improper cellular processing
of proSP-C may contribute to pulmonary fibrosis.
Pantelidis et al evaluated single nucleotide poly-
morphisms (SNPs) in four pro-inflammatory genes of
74 unrelated patients with clinical or biopsy-proven
CFA [15]. Candidate genes included tumour necrosis
factor-α (TNF-α), lymphotoxin-α (LTα), high affinity
TNF-α/LTα receptor 2 (TNF-RII), and interleukin-
6 (IL-6). Although no difference existed between
patients and controls with respect to genotype, allele,
or haplotype frequencies, a strong association between
carriage of the IL-6 (intron 4G) allele and the TNF-
RII (1690C) allele was observed in patients, but not in
controls [15]. Additionally, these investigators identi-
fied a strong linkage between the IL-6 (intron 4GG)
genotype and disease progression as measured by dif-
fusion capacity for carbon monoxide (DLCO), suggest-
ing that progression of disease may be associated with
decreased production of IL-6 [15].
Data implicating the major histocompatibility (HLA)
system are sparse. In one study, Fulmer et al found
no difference when comparing 35 separate antigens
of the HLA-A and HLA-B loci in 33 patients with
IPF with 329 healthy controls [16]. However, Libby
et al identified an increase in HLA-DR2 in patients
with IPF compared with controls [17]. It should be
noted that both of these studies were performed at a
time when the term ‘IPF’ encompassed many different
histopathological entities and may not be representa-
tive of UIP/IPF.
Environmental factors have also been thought to
contribute to the development of pulmonary fibrosis.
In 1977, Millar reported a case of infectious mononu-
cleosis in a woman with pulmonary fibrosis [18]. Since
that time, numerous investigators have evaluated a
possible link between viral infection and pulmonary
fibrosis. Egan et al first demonstrated evidence of
Epstein-Barr virus (EBV) replication in lower respi-
ratory tract epithelial cells of patients with CFA [19].
Yonemaru et al subsequently showed increases in both
cytomegalovirus (CMV) and EBV viral capsid anti-
gen IgG and complement fixation titres in patients
with IPF and connective tissue disease-related pul-
monary fibrosis (CTD-PF) compared with controls or
with patients with sarcoidosis or emphysema [20].
However, Wangoo et al evaluated the presence of
EBV RNA and DNA in lung biopsy specimens from
12 patients with CFA compared with biopsy spec-
imens from three normal controls and 12 patients
with other diffuse lung diseases [21]. These investiga-
tors reported no difference in EBV antibody staining
between patients and controls, no evidence for EBV
RNA by in situ hybridization in any patient, and no
difference in EBV DNA by polymerase chain reac-
tion (PCR) [21]. This supports their conclusion that
EBV infection is not associated with CFA. In con-
trast, Stewart et al observed that lung biopsy speci-
mens from 12 of 27 (44%) patients with IPF stained
positively for EBV compared with 3 of 28 (10%) con-
trols (p = 0.005) [22]. Additionally, 13 IPF patients
(48%) but only four controls (14%) were EBV-positive
by PCR (p = 0.007) [22]. These investigators subse-
quently showed that a rearrangement of EBV DNA
termed EBV WZhet was associated with active EBV
replication and was found in the peripheral blood of
16/27 (59%) IPF patients compared with 0/26 (0%)
lung transplant recipients and 1/24 (4%) normal blood
donors [23]. This suggested an association between
this DNA rearrangement pattern and IPF.
Together, these data suggest a potential link between
genetic or environmental factors that may predispose
to the development of UIP/IPF in a subset of patients.
Clinical features
Patients with IPF typically complain of a dry, non-
productive cough and dyspnoea. Dyspnoea is often
associated with exertion early in the disease course, but
usually progresses to shortness of breath at rest [24].
On physical examination, bi-basilar, end-expiratory
rales are appreciated in greater than 80% of patients
[25]. Clubbing is noted in up to half of all patients [7].
Late in the course of the disease, cyanosis of the lips
and fingers as well as signs of pulmonary hypertension
may be seen [26]. Laboratory evaluation of patients
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with suspected UIP is primarily to rule out alternative
causes of interstitial lung disease, such as sarcoidosis
or CTD-PF. There are no laboratory tests specific for
the diagnosis of UIP.
Restrictive pulmonary physiology is the classic
finding on pulmonary function testing in IPF [27].
When a patient has concurrent emphysema, lung
volumes may be relatively preserved [28]; however,
the DLCO is disproportionately reduced [29]. Severe
derangements in DLCO (<45%) and VC (<50%) are
associated with increased mortality [30].
Greater than 90% of patients with UIP will have
abnormal chest radiographs at the time of diagnosis
[7]. The characteristic pattern is diffuse bilateral inter-
stitial or reticulonodular infiltrates, most common in
the basilar and subpleural regions of the lung [31].
Pleural disease and lymphadenopathy are rare and
suggest an alternative diagnosis. Similar radiographic
findings may be seen in secondary causes of pul-
monary fibrosis including pneumoconioses and CTD-
PF [32].
High-resolution CT (HRCT) scanning has revolu-
tionized the diagnostic evaluation of patients with sus-
pected UIP. HRCT uses thin sections (1–2 mm slices)
with special reconstruction of images that allows for
enhanced visualization of lung parenchyma. Patterns
typically seen include coarse reticular or linear opac-
ities (intralobular and interlobular septal thickening)
with a predilection for the periphery and lower lobes of
the lungs, honeycomb cysts, and traction bronchiecta-
sis [33]. Ground glass opacities (ill-defined hazy zones
representing active alveolitis or fibrosis of the intralob-
ular and alveolar septae) can be present; if they are the
predominant pattern, it may indicate another subtype
of IIP [34,35]. Extensive honeycombing, septal thick-
ening, and a lack of ground glass opacities reflect a
poor prognosis.
Diagnostic certainty of IPF is improved with a surgi-
cal lung biopsy showing a UIP pattern. Transbronchial
lung biopsies usually do not allow for distinction
among the various idiopathic interstitial pneumonias
because of the limitations of the small biopsy size.
Video-assisted thoracoscopic surgical (VATS) biopsy
is the preferred method of obtaining lung tissue, as
this procedure offers a similar yield to open thoraco-
tomy [36]; VATS can be performed with relative ease
and decreased morbidity [37].
Histopathology
UIP typically demonstrates a heterogeneous appear-
ance, on low-power magnification, of normal-appea-
ring lung alternating with areas of peripheral fibro-
sis, interstitial inflammation, and honeycomb changes
[25], the so-called ‘temporal heterogeneity’ that is a
hallmark of the disease (Figure 1). The inflammatory
component is typically mild and consists primarily
of lymphocytes and plasma cells. Other inflamma-
tory cells such as neutrophils and eosinophils may
be present, but are not abundant. Dense, relatively
acellular, collagen bundles with smooth muscle meta-
plasia can be seen on higher-power magnification. At
the border between fibrotic and normal lung are col-
lections of fibroblasts/myofibroblasts, termed fibrob-
lastic foci, that are thought to represent the active
lesion of UIP (Figure 2) [38]. Alveolar epithelial injury
with hyperplastic type II pneumocytes is often seen at
areas of active fibrosis [39]. Honeycomb changes are
depicted by enlarged, cystic airspaces lined by hyper-
plastic type II pneumocytes.
The presence of fibroblastic foci may be an impor-
tant prognostic factor in IPF/UIP. Nicholson et al
devised a semi-quantitative scoring system which
grades four separate histological features (on a scale
from 0 to 6): extent of fibroblastic foci, extent of inter-
stitial mononuclear infiltrates, extent of established
Figure 1. Histopathology of UIP (low power). H&E-stained
whole mount section of lung from a patient with IPF. Note
the characteristic peripheral, subpleural location of fibrosis and
honeycomb change. These changes are heterogeneous, with
regions of lung parenchyma spared from fibrosis
FF
Figure 2. Histopathology of UIP (higher power). A hallmark of
UIP is the heterogeneity, represented by dense, acellular bundles
of collagen with smooth muscle metaplasia (arrow) in close
approximation to the fibroblastic focus (FF), a dense collection
of fibroblasts and myofibroblasts. Cuboidal epithelial cells lining
distorted airspaces (which may be undergoing apoptosis) are
seen overlying the fibroblastic focus
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fibrosis, and extent of intra-alveolar macrophage accu-
mulation [40]. These investigators showed that extent
of fibroblastic foci strongly correlated with decreased
Forced Vital Capacity (FVC) and DLCO as well as
mortality [40]. These data are in agreement with those
of King et al, who devised a separate semi-quantitative
scoring system to evaluate surgical lung biopsies of
patients with UIP [41]. Biopsy scores were obtained
for 14 histopathological features, which culminated
in the derivation of four factor scores: the ‘fibrosis
factor’, the ‘cellularity factor’, the ‘alveolar space cel-
lularity factor’, and the ‘granulation and young con-
nective tissue factor’ [41]. Controlling for age, gender,
and smoking status, these researchers demonstrated
that the granulation and young connective tissue score
was a strong predictor of survival [41]. Together, these
two studies suggest that the number of fibroblastic foci
and the extent of granulation tissue and young connec-
tive tissue seen on surgical lung biopsies of patients
with UIP/IPF may assist in predicting survival.
Mechanisms of fibrogenesis
Alveolar epithelial cells (AECs): targets of early
injury
The normal alveolar basement membrane is lined with
alveolar epithelial cells (AECs), which can be subdi-
vided into type I and type II pneumocytes. Ninety-five
per cent of the alveolar surface is covered with type
I pneumocytes. These cells are metabolically active
and harbour cell surface receptors for a variety of sub-
stances, including extracellular matrix (ECM) proteins,
growth factors, and cytokines. The remaining 5% of
alveolar lining cells consist of cuboidal epithelia (type
II pneumocytes). Type II pneumocytes secrete sur-
factant, facilitate transepithelial movement of water,
function as antigen presentation cells, and represent a
reservoir of progenitor cells that regenerate the alveo-
lar epithelium following lung injury [42].
It has been postulated that UIP may be the result of
abnormal ‘wound healing’ of the alveolar epithelium
after an injury [24,38]. In surgical lung biopsies of
patients with UIP, morphological changes including
hyperplastic type II cells, elongated type II cells, and
bronchiolar cells lining areas of honeycomb lesions
can be seen [43]. In addition, the apposition of
denuded basement membrane and the obliteration of
the airspace may result from lack of alveolar epithelial
cell proliferation and differentiation [44]. Evidence
for an altered AEC phenotype is also supported by
data demonstrating that AECs from patients with UIP
synthesize a different set of cytokeratins than AECs
from normal lung [45]. Epithelial cell function is
often determined by the type of cytokeratin expression;
thus, AECs in UIP may have both different form and
function when compared with alveolar epithelial cells
in normal lung.
Biopsy specimens of patients with UIP often demon-
strate areas of denuded alveolar basement membrane.
This implies either an increase in AEC death (necrosis
or apoptosis), a lack of proliferative capacity of AECs,
or a combination of both processes. Uhal et al demon-
strated that myofibroblasts from patients with fibrotic
lung disease secrete soluble factor(s) that induce apop-
tosis of human AECs [46]. A follow-up study from this
same group of investigators showed that angiotensin
II accounted for the majority of this effect; the addi-
tion of angiotensin II antibodies or receptor antago-
nists prevented fibrotic-lung fibroblasts from induc-
ing apoptosis in AECs [47]. Other evidence for AEC
apoptosis in the pathogenesis of UIP is provided by
Maeyama et al, who demonstrated an up-regulation
of the pro-apoptotic Fas–Fas ligand system in AECs
from patients with pulmonary fibrosis [48].
Classically, local expansion of type II AECs follow-
ing lung injury was thought to re-populate denuded
alveolar basement membranes in response to growth
factors such as hepatocyte growth factor and ker-
atinocyte growth factor [43]. Recent data from animal
models of lung injury also suggest that bone marrow-
derived progenitor cells can differentiate into type I
AECs [49,50], suggesting an additional mechanism for
re-epithelialization of damaged alveoli. However, this
mechanism has not yet been demonstrated in humans
and further studies are needed to determine whether
human bone marrow-derived cells possess the capacity
to transdifferentiate into alveolar epithelium.
In the normal alveolus, an intact AEC lining
may exert a homeostatic effect on local fibrob-
lasts/mesenchymal cells. A discontinuous and/or dam-
aged layer of AECs, as in patients with UIP, may
induce the secretion of stimulatory molecules or
result in diminished synthesis of inhibitory factors.
Prostaglandin E2 (PGE2) is a potent inhibitor of
fibroblast collagen synthesis and proliferation [51,52].
In broncho-alveolar lavage (BAL) fluid from patients
with UIP, PGE2 levels have been shown to be approx-
imately half those of control patients [53], suggesting
that loss of AECs or the diminished capacity of AECs
to synthesize PGE2 may contribute to the pro-fibrotic
milieu in the alveolar space.
In addition to prostanoids, AECs also synthesize
numerous growth factors and cytokines that activate
fibroblasts/mesenchymal cells. AECs are the primary
source for transforming growth factor-beta (TGF-β)
[54], a critical cytokine in the transdifferentiation
of fibroblasts into the activated myofibroblast phe-
notype. Additionally, AECs produce platelet-derived
growth factor (PDGF) [55], tumour necrosis factor
alpha (TNF-α) [56], and endothelin-1 [57]. PDGF is
a potent mitogen and chemoattractant for fibroblasts;
PDGF mRNA and protein have been shown to be up-
regulated in epithelial cells of patients with IPF [55].
TNF-α is secreted by hyperplastic type II AECs in pul-
monary fibrosis [56,58] and promotes DNA synthesis
and proliferation of fibroblasts [59]. Endothelin-1 has
also been shown to stimulate fibroblast DNA synthesis
and proliferation as well as to induce transdifferentia-
tion of fibroblasts to myofibroblasts [60].
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AECs also likely contribute to the pathogenesis of
UIP by regulating the plasminogen activation sys-
tem. The plasminogen activation system is critical
to normal wound healing [61]. Plasminogen, acti-
vated by tissue-type plasminogen activator (tPA) or
urokinase-type plasminogen activator (uPA) to plas-
min, is the primary fibrinolytic enzyme responsible
for degrading fibrin clots and allowing for wound re-
epithelialization. Plasminogen, and thus plasmin activ-
ity, is negatively regulated by plasminogen activator
inhibitors (PAIs). Animal models suggest that over-
expression of PAIs (which inhibits plasmin activity)
promotes fibrosis, whereas lack of PAIs (allowing
greater plasmin activity) prevents the formation of
significant fibrosis [62]. Additionally, overexpression
of uPA was shown to decrease fibrosis in a murine
model [63]. In UIP, the plasminogen activation system
has been implicated in regulating fibrin turnover and
ECM degradation [42]. It is known that AECs synthe-
size both PAI-1 and urokinase [64,65] as well as the
urokinase receptor, uPAR [66]. Kotani et al showed
that BAL fluid from patients with IPF contains signif-
icantly greater amounts of tissue factor and PAIs than
normals, whereas uPA levels were similar between the
two groups [67]. These studies suggest that the alveo-
lar microenvironment in IPF favours a pro-coagulant,
anti-fibrinolytic state that favours ECM accumulation
and retards alveolar re-epithelialization.
Fibroblasts/myofibroblasts: key effector cells in
fibrogenesis
Fibroblasts are the most versatile of the connective-
tissue cell family and possess a remarkable capacity to
undergo various phenotypic conversions between dis-
tinct but related cell types. This phenotypic plasticity
is an important feature of the responses to many types
of tissue injury [61]. Fibroblasts participate in repair
and regenerative processes in almost every human tis-
sue and organ. Their primary function is to secrete
ECM proteins that provide a tissue scaffold for nor-
mal repair events such as epithelial cell migration.
Eventual dissolution of this scaffold and apoptosis of
fibroblasts/myofibroblasts are critical for restoration of
normal tissue architecture [68,69].
Fibroblasts with an activated myofibroblast phe-
notype have been described in the fibroblastic foci
that characterize UIP [39,70]. Gabbiani et al first
described the transient appearance and disappearance
of these so-called myofibroblasts in the granulation tis-
sue of healing cutaneous wounds [71]. Myofibroblasts
possess ultrastructural features intermediate between
fibroblasts and smooth muscle cells and have been
defined by their ability to express contractile pro-
teins [72]. This contractile function is important in
the re-epithelialization process by bringing wound
margins closer together. In addition, myofibroblasts
represent an ‘activated’ fibroblast phenotype with
high synthetic capacity for ECM proteins [73,74],
growth factors/cytokines [75], growth factor recep-
tors [76], integrins [77], and oxidants [78,79]. Per-
sistence of myofibroblasts in areas of active fibrosis
appears to be a consistent finding in the pathology of
human fibrotic diseases involving diverse organ sys-
tems [38,80].
Several studies have attempted to characterize the
phenotype of fibroblasts in UIP/IPF. These studies
have sometimes produced conflicting results, which
may be related to inherent tissue fibroblast heterogene-
ity and changes in cellular microenvironment, includ-
ing in vitro culture conditions. Fibroblasts derived
from fibrotic tissue have been reported to demon-
strate both high and low proliferative capacities
[81–83]; lower rates appear to be associated with
more advanced fibrosis [81]. Fibrotic lung fibrob-
lasts demonstrate anchorage-independent growth in
soft agar, whereas normal fibroblasts do not [84].
In vivo apoptotic rates of fibroblasts/myofibroblasts
from UIP appear to be lower than those found
in the fibromyxoid connective tissue of bronchi-
olitis obliterans organizing pneumonia [85]; para-
doxically higher rates have been observed in in
vitro culture of UIP fibroblasts [83]. The discrepan-
cies in growth, apoptosis, and myofibroblast pheno-
type most likely reflect differences in culture tech-
nique, passage number, and inter-patient variability.
Newer techniques, such as laser capture microdis-
section (LCM), have been proposed to address these
inherent problems related to tissue heterogeneity
[86]. Coupled with gene expression and protein
expression arrays, LCM of fibroblastic foci fibrob-
lasts will allow investigators to define the pheno-
type of the active lesion in UIP fully and more
accurately.
UIP fibroblasts possess a highly synthetic phenotype
and produce a number of ECM proteins and inte-
grin molecules [39,70,83,87,88]. This is accompanied
by imbalances in the production of matrix metallo-
proteinases (MMPs) and tissue inhibitors of metal-
loproteinases (TIMPs) [83,89]. In particular, TIMP-2
expression by UIP fibroblasts/myofibroblasts appears
to contribute to the irreversible structural remod-
elling in this disease [90–92]. Myofibroblasts in
UIP have been shown to secrete angiotensin pep-
tides that may induce apoptosis of adjacent alve-
olar epithelial cells [46,47,93]. Other phenotypic
characteristics described in UIP fibroblasts include
enhanced migratory capacity [94], increased fibroblast
contractility [95], and diminished cyclooxygenase-2
expression/prostaglandin E2 synthesis [96]. Moreover,
fibroblasts themselves express surface receptors such
as CD40 typically associated with immune cells and
are capable of producing a number of chemokines and
cytokines [97–99]. Thus, fibroblasts and myofibrob-
lasts, with their variegated phenotypes and multiple
roles, appear to be key effector cells in the pathogen-
esis of fibrosis.
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Neutrophils and other inflammatory cells: effector
cell or bystander?
The role of neutrophils and other inflammatory cells
such as eosinophils, mast cells, and lymphocytes in
the pathogenesis of IPF is largely unknown. Neu-
trophils have been more extensively studied in pul-
monary fibrosis than other inflammatory cells, but data
demonstrating an active role for these cells in the
late stages of UIP/IPF are scant. A number of studies
have demonstrated an association between the pres-
ence of inflammatory cells and disease [100–107];
however, the precise cause–effect relationship is
unclear.
Neutrophils circulate in blood as quiescent cells
and express small quantities of surface proteins that
serve as adhesion molecules [108]. Once recruited
to sites of injury, neutrophils undergo a variety of
functional changes affecting cellular adhesion, trans-
migration, and the release of toxic products. Neu-
trophils contain a large number of hydrolytic enzymes
and other toxic molecules in their granules, including
neutrophil elastase, lysozyme, myeloperoxidase, and
members of the MMP family [109]. In addition, these
cells can generate various oxidant species, including
superoxide anion (O2−), hydrogen peroxide (H2O2),
and hypochlorous acid (HOCl) [110,111]. Extracel-
lular release of these toxic substances can result in
lung parenchymal and stromal cell injury, as well as
degradation of key ECM components of lung tissue. In
addition to elastin, neutrophil elastase can degrade col-
lagen types III and IV, laminin, fibronectin, and core
proteins of proteoglycans [112]. Furthermore, elastase
can cleave pro-enzyme forms of MMPs into the fully
active form of these enzymes [113]. Elastase burden
was found to be increased in BAL fluid from patients
with IPF [107], suggesting a potential role for this
protease in the pathogenesis of IPF.
Of the enzymes found in neutrophil granules, MMPs
(notably MMP-2 and MMP-9) have been most closely
linked with degradation of ECM components in UIP
[89,91]. Exuberant expression of neutrophil-derived
serine proteinases and MMPs has also been observed
in the airspace and lung interstitium of patients with
IPF [91,114]. These proteases may propagate abnor-
mal tissue remodelling in IPF by damage to alveolar
basement membranes. An alternative hypothesis sug-
gests that enhanced protease expression may be overly
compensated for by even greater expression of TIMPs
and other anti-proteases in the lung interstitium of IPF
patients, which would have the net effect of diminished
proteolytic activity and progressive ECM accumula-
tion. In support of this concept, Selman et al observed
that IPF lungs display increased TIMP expression
compared with MMP expression, suggesting an imbal-
ance between MMPs and TIMPs [89].
In addition to proteolytic enzymes, the neutrophil
is an important source of reactive oxygen species
[111]. Nicotinamide adenine dinucleotide phosphate
(NADPH)-oxidase is the predominant enzyme respon-
sible for oxidant production. Upon neutrophil acti-
vation, NADPH-oxidase generates O2ž−, which dis-
mutates to H2O2. Neutrophil-derived myeloperoxidase
then catalyses the conversion of H2O2, a relatively
weak oxidant, into the more potent oxidant HOCl
[115]. HOCl and other oxidants may directly con-
vert pro-metalloproteinases into active enzymes [116],
further altering the protease–anti-protease balance.
Superoxide anion generated by activated neutrophils
can also perpetuate tissue injury by reacting with
nitric oxide released by neutrophils, macrophages,
endothelial cells, and fibroblasts to form the highly
reactive species peroxynitrite and peroxynitrous acid
[117]. These metabolites can induce lipid peroxida-
tion in vitro; enhanced peroxynitrite activity has been
observed in the lungs of patients with IPF [118]. Fur-
thermore, oxidants produced by neutrophils and myofi-
broblasts may mediate cross-linking of ECM pro-
teins that contribute to the remodelling process [119].
Finally, reactive oxygen species can further amplify
neutrophilic inflammation and injury by activating key
cellular transcription factors, including NF-κB, AP-
1, and JAK-STAT, critical for the activation of pro-
inflammatory and pro-fibrotic genes [120,121].
It remains possible that neutrophils do not play
an active role in the pathogenesis of IPF, but might
instead be ‘bystander’ cells recruited in response
to mediators released during the fibrotic response.
Notably, a family of chemotactic cytokines, referred
to as CXC chemokines, exerts potent neutrophil
chemoattractant activity and are critical mediators
of angiogenesis [122]. In human pulmonary fibrosis,
the CXC chemokine family, which consists of both
angiogenic and angiostatic molecules, is thought to
be important in influencing angiogenesis [123,124].
It has been shown that the expression of the neu-
trophil chemotactic CXC chemokines interleukin-
8 (IL-8/CXCL8) and epithelial neutrophil-activating
peptide (ENA)-78/CXCL5 is markedly increased in
the BAL fluid and cells isolated from patients with
UIP, compared with patients with sarcoidosis or nor-
mal volunteers [125]. IL-8/CXCL8 mRNA expres-
sion positively correlated with the degree of BAL
neutrophilia. However, there was a distinct lack of
neutrophilic infiltration in areas of lung where ENA-
78/CXCL5 was expressed, suggesting a role for ENA-
78/CXCL5 in UIP that is distinct and separate from
neutrophil chemotactic effects [124]. Similarly, in a
murine model of bleomycin-induced pulmonary fibro-
sis, these investigators demonstrated that macrophage
inflammatory protein (MIP)-2, the murine functional
homologue of IL-8 [126], mediates angiogenesis but
not neutrophil recruitment [127]. Specifically, neutral-
ization of MIP-2 activity resulted in decreased angio-
genesis and attenuated pulmonary fibrosis, but had no
effect on the influx of neutrophils into the lung, again
suggesting that the neutrophil chemoattractant proper-
ties and angiogenic properties of the CXC chemokine
family may be quite distinct.
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It should be noted that the role of angiogenesis in the
development of UIP/IPF remains controversial. Angio-
genesis is required for initiation of wound healing
and formation of granulation tissue [128]. However,
as scar tissue matures, there is an ordered regression
of vessels with deposition of collagen and contraction
of the wound bed by myofibroblasts [128]. In sup-
port of the wound healing model of UIP/IPF, Renzoni
et al recently observed a net vascular regression in
lung biopsy specimens from patients with CFA or with
fibrosing alveolitis associated with systemic sclerosis,
compared with control samples [129]. These investiga-
tors demonstrated decreased vascular density as well
as decreased total vascular area in specimens of CFA
compared with normals. This finding is in agreement
with the earlier findings of Cassan et al, who identified
decreased mean capillary surface area in nine patients
with CFA compared with normal controls [130].
Eosinophils were first postulated to be involved
in the pathogenesis of IPF in 1977, when Reynolds
et al demonstrated a significant increase in BAL
fluid eosinophils from patients with pulmonary fibro-
sis compared with controls [103]. Further investiga-
tion revealed that a higher eosinophil count in BAL
fluid predicted failure to respond to corticosteroid
therapy and a greater likelihood of disease progres-
sion [131]. Elevated eosinophil counts and increased
levels of an eosinophil-specific protein (eosinophil
cationic protein, ECP) in BAL fluid have been shown
by other investigators [132,133], but the role of
eosinophils in fibrogenesis remains obscure. Wells
et al compared BAL fluid cellularity from patients
with IPF and patients with scleroderma-associated
pulmonary fibrosis. These investigators observed that
eosinophil counts were higher in patients with IPF
than in patients with scleroderma, suggesting that
eosinophils might play a pathogenetic role in IPF and
contribute to a worse prognosis [101].
Mast cells have been found in increased numbers in
biopsy specimens of patients with IPF [134,135]. In
addition, mast cell products, notably mast cell tryptase
and histamine, have been recovered from the BAL
fluid of patients with IPF [136]. Ultrastructurally, on
electron microscopy, mast cells in tissue specimens
of IPF show evidence of degranulation [137] and
close apposition to fibroblasts [138], suggesting a
potential role for mast cells in the pathogenesis of
UIP. Incomplete degranulation on electron microscopy
suggests a chronic ‘piecemeal’ degranulation process
which contrasts with the total degranulation observed
in anaphylaxis [139]. This ‘piecemeal’ degranulation
may result in ongoing tissue injury that promotes
fibrosis.
Therapeutic options for pulmonary fibrosis
Currently, no effective treatment for IPF exists. Ther-
apeutic options for IPF have traditionally focused
on the paradigm that chronic inflammation leads
to tissue injury and fibrosis; thus, corticosteroids





























Figure 3. Overview of some of the key pathogenetic mechanisms in UIP/IPF. Following an unidentified insult, alveolar epithelial cells
become injured and delayed re-epithelialization leads to a denuded, disrupted basement membrane. A fibrin clot forms early and
serves as a provisional matrix for the migration and proliferation of reparative type I alveolar epithelial cells. Angiogenic factors may
be elaborated, leading to the formation of nascent vasculature early in the disease process. Neutrophils secrete pro-inflammatory
mediators, reactive oxygen species (ROS) and MMPs, while recruited lymphocytes elaborate the Th2-type cytokines, IL-4 and
IL-13. Fibroblasts migrate into the wound and produce extracellular matrix (ECM) proteins and mediators such as angiotensin II
which may further promote alveolar epithelial cell apoptosis. Alveolar macrophages and epithelial cells secrete TGF-β1, which
promotes myofibroblast differentiation, increases ECM production, and inhibits apoptosis of fibroblasts/myofibroblasts. As ECM
deposition progresses, regression of blood vessels may occur. Reciprocal communication between alveolar epithelial cells and
mesenchymal cells results in a ‘positive feedback loop’ that promotes ongoing fibrosis and destruction of alveolar architecture
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IPF. However, no prospective, randomized, placebo-
controlled trials evaluating their efficacy in the treat-
ment of IPF have been performed [25] and recent
data suggest that corticosteroids may be harmful rather
than beneficial in these patients [140]. Regimens con-
taining other immunosuppressive and cytotoxic agents,
such as cyclophosphamide [141], azathioprine [142],
and colchicine [143], have been used but confer no
benefit compared with steroids alone or, in some
cases, placebo alone. A newer anti-fibrotic agent, pir-
fenidone, has been proposed in patients with IPF
[144]; a phase III, randomized, multi-centre trial with
this agent is planned. Interferon-γ has also been
shown to have promising effects in the treatment of
IPF, although a preliminary study showing efficacy
included only 18 patients (nine who received pred-
nisolone and nine who received prednisolone plus
interferon-γ [145]. Additionally, in this pilot study,
survival benefits were not assessed. Recently, a phase
III, double-blinded placebo controlled multi-centre
randomized trial of interferon-γ in IPF was completed,
but the results of this trial have not yet been published.
Conclusion
IPF is a progressive, fibrotic process of the distal
airspaces and interstitium of the lung that is charac-
terized by the histological pattern of usual interstitial
pneumonia (UIP). Therapy for this disease with glu-
cocorticoids and other immunomodulatory agents is
largely ineffective. UIP is not associated with a signifi-
cant inflammatory response; rather, it appears to result
from dysregulated epithelial–mesenchymal communi-
cation (Figure 3). Only recently have we begun to
identify some of the key intracellular pathways and
mediators that play a role in the pathogenesis of UIP
[146,147]. As our understanding of the pathogenetic
mechanisms in UIP/IPF increases, the development of
more targeted approaches that interfere with fibroge-
nesis will help to combat this progressive, disabling
and fatal disease.
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